At a glance
ClinicalIndex Comparison Record- ✓Karnofsky performance status (KPS) ≥70
- ✓No more than 5 metastatic sites involving liver, lung, or bone
- ✓Lesion size must permit safe delivery of sterilizing radiation doses per protocol
- ✓No age limit
- ✕Inability to be followed longitudinally per protocol
- ✕Technical inability to achieve required radiation dose within safe constraints
- ✕Pregnant or nursing women
- ✕Contraindications to radiation therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer
In Brief
A clinical study evaluating Hypofractionated Stereotactic Body Radiation Therapy for Breast Cancer, Metastatic. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate whether radiosurgery, along with standard chemotherapy, immunotherapy (the treatment of cancer by modulating the immune system and immune response), or hormonal therapy, affects the quality and length of life. The standard therapy is surgery, radiation therapy, or chemotherapy alone or in any combination. A second purpose of this study is to determine if the levels of a special type of protein (called cytokines) found in the blood are related to the quality of life while on this treatment.
Study Details
Timeline
Interventions
Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.